Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lumg Cancer (NSCLC) - TOLEDO
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- EUCTR2005-004029-24-NL
- Lead Sponsor
- Thoracale Oncologie Groep Antwerpen TOGA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
-completely resected (RO) pathological stage IB-II NSCLC
-performance status WHO<=1
-age 18-75 years
-considered fit for chemotherapy
-adequate haematological, renal and hepatic functions
-written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
-previous chemo- or radiotherapy for NSCLC
-second active primary malignancy
-serious concomitant systemic disease that, in the opinion of the investigator, would compromise the safety of the patient
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method